Cellular Technology Limited — Stock, Pipeline & Market Cap

Is this your company? Claim your profile to update info and connect with investors.

Private Company

Funding information not available

Overview

Cellular Technology Limited (CTL) is a long-established, private US company that has become a cornerstone in the immune monitoring field with its ImmunoSpot® platform. The company provides an end-to-end ecosystem for high-content ELISPOT/FluoroSpot analysis, encompassing proprietary instrumentation, optimized assay kits, sophisticated analysis software, and expert contract laboratory services. Its technology is critical for quantifying antigen-specific T and B cell responses, making it essential for vaccine development, immunotherapy research, and infectious disease studies. CTL operates as a specialized tools and services provider, generating revenue through product sales and CRO services to academic, biopharma, and government clients globally.

Infectious DiseaseOncologyAutoimmune

Technology Platform

Integrated ImmunoSpot® platform for ELISPOT/FluoroSpot assays, including proprietary analyzers, optimized assay kits, and sophisticated software (IntelliCount™, SpotStat™) for automated, high-content immune cell analysis.

Opportunities

Growing demand for standardized immune monitoring in vaccine development and immunotherapy trials presents a major opportunity.

Expansion of B cell assay applications and software-as-a-service models offer new revenue streams.

The need for validated, GLP-compliant assays in clinical research strengthens the value proposition for both products and CRO services.

Risk Factors

Core ELISPOT technology faces potential displacement by emerging, higher-plex single-cell analysis platforms.

The company is dependent on continued biopharma R&D investment and competes with both niche specialists and large life science tool conglomerates.

As a private company, access to growth capital may be more limited compared to public peers.

Competitive Landscape

CTL competes in the immune monitoring tools segment against other specialized ELISPOT reagent providers like Mabtech and divisions of large corporations (e.g., BD, Thermo Fisher Scientific). Its primary competitive advantage is its fully integrated, software-driven platform focused on standardization and objective analysis, differentiating it from providers who sell components alone. In the CRO space, it competes with central labs and other specialty immunology service providers.

More companies in Immunotherapy / Immuno-Oncology →More companies in United States →